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Biofilm formation is the preferred mode of growth lifestyle for many microorganisms, including bacterial and fungal human 
pathogens. Biofilm is a strong and dynamic structure that confers a broad range of advantages to its members, such as adhesion/
cohesion capabilities, mechanical properties, nutritional sources, metabolite exchange platform, cellular communication, 
protection and resistance to drugs (e.g., antimicrobials, antiseptics, and disinfectants), environmental stresses (e.g., dehydration 
and ultraviolet light), host immune attacks (e.g., antibodies, complement system, antimicrobial peptides, and phagocytes), and 
shear forces. Microbial biofilms cause problems in the hospital environment, generating high healthcare costs and prolonged 
patient stay, which can result in further secondary microbial infections and various health complications. Consequently, both 
public and private investments must be made to ensure better patient management, as well as to find novel therapeutic strategies 
to circumvent the resistance and resilience profiles arising from biofilm-associated microbial infections. In this work, we present 
a general overview of microbial biofilm formation and its relevance within the biomedical context.
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The social life of microorganisms - Microorganisms 
can colonise virtually every environment on Earth, in-
cluding soils, water, and air-liquid interfaces - each of 
which present distinct physicochemical conditions. The 
ability to quickly adapt to different habitats can be ex-
plained, at least in part, by the fact that microbial cells 
are the most ancient representative lineage of living or-
ganisms and they have experienced many changes in 
environment over their billions of years of existence. 
This evolution has permitted the development of plas-
tic genomes and, consequently, plastic metabolisms in 
many microorganisms, which allows for rapid mutation 
(plastic response) when faced with adversity.(1) With this 
perception in mind, curiously, microorganisms have 
been developing an amazing ability to resist diverse, and 
sometimes drastic, environmental insults and stresses. 
They have learned to live together in an “organised and 
well-orchestrated community” - the so-called “biofilm”.
The word “community” is derived from the Old 
French “comuneté”, which comes from the Latin “com-
munis”, meaning “shared in common”. Community can 
be defined as a social group (an assemblage of interacting 
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populations) of any size, whose members occupy a given 
area or a specific locality, share common characteristics 
or interests, establish communication platforms, and of-
ten have a common heritage. In the microbial world, the 
concept of living together can be applied to all of these 
avenues, contemplating the integration and fulfilment of 
all of the needs of a group. Furthermore, living together 
stimulates and promotes several beneficial features for 
microorganisms compared to living a solitary life. Un-
doubtedly, protection and tolerance/resistance are the 
most beneficial aspects of being an active participant 
within a well-established microbial community.(2)
Biofilm: the preferred microbial lifestyle - The idea 
that microorganisms are able to live together and form 
biofilms is indeed an old one, dating back to the classi-
cal and primordial studies by Antonie van Leeuwenhoek 
(1632-1723), who first reported the concept of “microbial 
aggregation” on the surface of teeth, and Louis Pasteur 
(1822-1895), who described the microbial community to 
be the cause of wine becoming acetic.(3) Generally, bio-
films are defined as communities of properly organised 
microorganisms (as a typical social cooperation system) 
attached to an inert or living substrate (Fig. 1) and embed-
ded in a self-produced extracellular matrix (also called 
extracellular polymeric substance) composed of (glyco)
proteins, (glyco)lipids, (mono)/(poly)saccharides, extra-
cellular DNA, minerals, and water, which works like an 
adhesive favouring cell-cell and cell-substrate interac-
tions. Additionally, the biofilm extracellular matrix can 
contain host-derived components, such as human serum, 
saliva glycoproteins, and vaginal excretions.(4-8)
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The chemical constituents of the extracellular matrix 
are responsible for maintaining biofilm architecture, 
stabilising it through the formation of intermolecular 
interactions, cross-linkages of multivalent cations, and 
an ingrained network of biopolymers. All these extracel-
lular matrix properties help to form a robust shelter that 
offers a protected and nutritionally rich ecological niche, 
contributing to microbial survival, molecule exchanges, 
communication (by quorum sensing signalling, a cell 
density-dependent communication system that regulates 
cooperative behaviours), and proliferation. The extracel-
lular matrix is an extremely dynamic structure that is 
constantly remodelled to suit the environment and liv-
ing conditions of the cells, as well as to provide physico-
chemical stability to the biofilm architecture.(4-8)
Biofilm formation is a sequential, finely orchestrated, 
multi-step phenomenon governed by a number of physi-
cal, chemical, and biological factors: attachment, micro-
colony formation (proliferation), maturation, and disper-
sion (desorption/detachment) (Fig. 2).(8-10) During these 
phases, microbial biofilms form three-dimensional (3D) 
structures that are separated by water channels, which 
allow the entry of nutrients and oxygen, as well as the 
discharge of waste products. Moreover, the creation of a 
myriad of microenvironments within the biofilm commu-
nity allows for complex microbial interactions, including 
chemical and electrochemical cell -to -cell communication 
and enhanced horizontal gene transfer.(6,11) In the clinical 
context, horizontal gene transfer can determine, for in-
stance, the acquisition of antimicrobial resistance genes, 
a phenomenon well-known in bacteria. The presence of 
environmental DNA (eDNA; which is a complex mixture 
of cellular genomic DNA from living organisms within a 
population and coming from autolysis, uncontrolled cell 
lysis or active secretion systems via membrane vesicles), 
and extracellular DNA (e.g., coming from viruses) in a 
biofilm is widespread and constitutes an evolutionary ad-
vantage. eDNA plays many relevant roles, including as 
a structural molecule for biofilm stability, as a source of 
energy and nutrients (carbon, nitrogen, and phosphorus), 
and as a means of horizontal gene transfer by transfor-
mation of competent sister bacteria.(12)
It is important to emphasise that biofilms have varied 
structures, 3D architectures, and chemical compositions, 
and that these factors are influenced by the particular 
microbial genera, species, and strains, as well as by the 
environmental conditions.(4-6,8,11,13-15) Interestingly, expos-
ing the microorganism to sub-inhibitory concentrations of 
classical antimicrobial drugs can induce biofilm forma-
tion and the expression of additional virulence attributes. 
For instance, the administration of sub-inhibitory doses of 
aminoglycosides was able to trigger biofilm formation in 
the bacterial pathogens Escherichia coli and Pseudomo-
nas aeruginosa.(16) Similarly, mature biofilms of Candida 
albicans, when challenged with sub-minimum inhibi-
tory concentrations (MICs) of fluconazole, were able to 
secrete higher quantities of aspartic peptidases (Saps), a 
well-recognised multitask virulence factor, compared to 
untreated biofilms.(17) Undoubtedly, biofilm formation is 
an extremely advantageous outcome for microbial sur-
vival, development, and evolution.
Microbial biofilm: a real problem in the clinical set-
ting - The incidence of biofilm-associated infections is 
increasing annually, and their impact on health and ser-
vices may be grossly underestimated. The National Insti-
tutes of Health estimated that both bacterial and fungal 
biofilms were responsible for over 80% of all nosoco-
mial infections in the USA.(18) Biofilm-related illnesses 
can be divided into three main types: (i) device-related 
biofilm disease, (ii) non-device-related chronic biofilm 
disease, and (iii) biofilm-related device malfunction.(19) 
Biofilm-associated infections represent a major problem 
in the hospital setting worldwide due to their recalcitrant 
nature and to difficulties in treatment.(9,10,20,21) Microbial 
infections related to biofilms are usually treated with 
high doses of antimicrobials (usually a combination of 
Fig. 1: biofilm formation by the filamentous fungus, Scedosporium apiospermum, an opportunistic human pathogen, on both abiotic and biotic 
surfaces. The biofilm on the polystyrene substrate was detected by safranin staining (A) and by scanning electron microscopy (B). The co-
culture of S. apiospermum conidia with lung epithelial A549 cells for 24 h (C) and 48 h (D) revealed a dense mycelial mass (a typical biofilm 
structure) covering the lung epithelial cells, as evidenced by Giemsa staining. Histopathological section stained by hematoxylin and eosin 
showing many hyphae in the skin biopsy from human infected tissue (E). Bars, 50 µm. For more detail see Mello et al.(7) Image credit: Fig. E 
was kindly gifted by Dr Stacy Beal, Assistant Professor, University of Florida, College of Medicine, Department of Pathology, Immunology 
and Laboratory Medicine, USA.
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different drugs) for a prolonged period of time.(9,22-24) 
Such a treatment regimen can provoke unpleasant collat-
eral consequences for the patient, and in some cases will 
involve the “traumatic” (with a significant physical and 
psychological burden) replacement or removal of medi-
cal implants.(9) Consequently, biofilm formation is a ma-
jor contributor to the unacceptably high mortality rates 
associated with microbial infections, particularly those 
caused by bacterial and fungal pathogens.(19,22) Corrobo-
rating this statement, more than 500,000 deaths per year 
occur due to biofilm-related infections in the USA.(25)
The biofilm lifestyle is associated with the chronic 
nature of microbial infections (Table I),(26-34) particularly 
in hospitalised patients under care with a medical device 
(Table II),(35) resulting in prolonged hospital stay and 
added healthcare costs to both public and private institu-
tions worldwide.(9,10,18-24) It has been estimated that, for 
hospitals in the USA alone, the annual cost for treating 
device-related biofilm infections is over eleven billion 
dollars.(36) To compound this problem, medical devices 
and tissue engineering constructs are susceptible to col-
onisation by different microbial groups and can induce 
(i) device malfunction, (ii) chemical degradation of bio-
materials, and/or (iii) infectious processes by different 
classes of microorganisms.(37)
In addition, biofilms can serve as a source of local 
and systemic infections, especially in patients confined 
in intensive care units. For instance, biofilm formation 
by Candida spp. in the respiratory tract of gravely ill pa-
tients (i.e., immunocompromised patients) can promote 
the development of ventilator-associated bacterial pneu-
monia by P. aeruginosa and Staphylococcus aureus.(38) A 
single microbial species or a consortia of multiple species 
can cohabitate within a mature biofilm structure. Poly-
microbial biofilms are considered to be even more com-
plex communities of microorganisms that cooperatively 
interact in an altruistic manner, and are commonly ob-
served in natural environments and in in vivo infections 
(Fig. 3), imposing additional complications in the man-
agement and treatment of diseases.(39,40) Dental plaque is 
a typical polymicrobial biofilm (main cariogenic bacteria 
are streptococci, actinomycetes, and lactobacilli) that 
forms on the surfaces of teeth and, if inadequately con-
trolled, can lead to dental caries (which can lead to tooth 
decay) or periodontitis.(41) Another relevant issue when 
considering polymicrobial biofilms is the variable and 
metabolic-rich activities in this closed community that 
favours cooperation (which can be comparable to that 
in the tissues of multicellular organisms) and protection 
(e.g., the presence of catalase-producing microorganisms 
that will protect non-catalase-producing species from the 
detrimental effects of hydrogen peroxide).(42)
Biofilm formation is considered a virulence deter-
minant in microorganisms, and it strongly contributes 
to microbial resistance to conventional antimicrobial 
agents, host protective immune responses, hostile en-
vironmental pressures/stresses, predation, and shear 
forces.(43-47) Interestingly, dispersed biofilm microbial 
cells have a greater capability to cause cytotoxicity, vir-
ulence, and mortality than their planktonic counterparts.
(48) The biofilm tolerance/resistance phenomenon is as-
sociated with (i) a high density of microbial cells form-
ing the mature biofilm structure, which presents distinct 
growth and metabolic rates, (ii) the low penetration of 
drugs through the extracellular matrix and/or covalent 
binding of antimicrobial drugs to the extracellular ma-
TABLE I
Human diseases associated with biofilm development
Chronic prostatitis Orthopedic infections (e.g., osteomyelitis)
Chronic wounds Otitis media
Chronic lung infection in cystic fibrosis patients Periodontal disease (e.g., gingivitis)
Dental caries Tuberculosis
Endocarditis Upper respiratory infections (e.g., rhinosinusitis)
Keratitis Urinary tract infections
Fig. 2: biofilm development steps produced by microorganisms. The image indicates the adherence of a microbial community to the surface, 
followed by microcolony formation, the maturation of the biofilm 3D architecture (note the presence of different cells, including the persisters, 
which are represented by light blue circles) with the presence of an extracellular polymeric matrix (represented by an orange cover) and, finally, 
its dispersion, which can lead to the colonisation and formation of a new biofilm structure in a distinct place, as well as the persistence of the 
infectious disease.
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trix components, (iii) the differential expression (down 
or upregulation) of drug targets, (iv) the efflux of intra-
cellular drugs through pumps and transporter proteins, 
(v) the upregulation of different classes of resistance 
genes and alteration in the cellular stress responses, and 
(vi) the presence of a small and distinct subpopulation of 
microbial cells called ‘persisters’ that is spontaneously 
formed within a biofilm. Persisters are defined as dor-
mant, metabolically inactive and non-dividing variants 
of regular cells and are highly recalcitrant to antimicro-
bial challenge.(43-47) Indeed, the mechanisms underlying 
biofilm resilience are complex and multifactorial; in this 
way, one or many of these previously proposed phenom-
ena may be operational and contribute to the broad range 
of resistance against multiple stressors.
The relevance of the microbial biofilm for numerous 
biotechnological and biomedical areas is reflected, at least 
in part, by the significant increase in the number of publi-
cations about biofilms over recent years, confirming that 
it is a current and vigorous research field. Herein, we have 
assimilated data gleaned from the available literature, in 
which the search was performed on April 1st, 2018, using 
the PubMed database (www.pubmed.com). To accomplish 
this, the keyword “biofilm” was added to the “Advanced 
Search Builder tool” and only papers published in English 
containing these words in the title/abstract were selected. 
In addition, the list of results was exported to the EndNote 
software in order to eliminate duplicated references. Our 
results revealed a total of 30,453 publications (research 
papers, short communications, (mini)reviews, and book 
chapters) concerning studies on biofilms during the pe-
riod 1980-2017 (Fig. 4A). A meticulous data analysis in-
dicated that the number of publications increased signifi-
cantly when the periods 1990-1999 (≈ 612%), 2000-2009 
(≈ 4435%), and 2010-2017 (≈ 12550%) were compared to 
the period 1980-1989 (Fig. 4B).
Future efforts should explore the integration of di-
verse methods employed to successfully combat mi-
crobial biofilm formation, which has become a severe 
problem worldwide. In this context, biofilm inhibition 
and destruction represent high value targets for the de-
velopment of new antimicrobial drugs and/or new anti-
biofilm strategies (Fig. 5), particularly against the ex-
tracellular matrix, which acts as a sponge.(49) Two major 
approaches can be taken into account to combat biofilm-
related infections: obstruction of biofilm formation (e.g., 
by modifying the physicochemical properties of inert 
surfaces through coating or impregnating surfaces with 
antimicrobial compounds, or by targeting specific surface 
microbial adhesins using lectins or antibodies), and dis-
articulation of the mature biofilm (e.g., by destabilising, 
weakening, or destroying the extracellular matrix compo-
TABLE II
Medical devices and implants in which microbial biofilm formation is a problem
Abdominal drains Intrauterine contraceptive devices
Artificial voice prostheses Intravenous catheters
Artificial hip prostheses Nephrostomy tubes
Breast implants Orthodental prosthetics
Cannulation Orthopedic devices
Cardiac pacemakers Peritoneal dialysis catheters 
Cardiovascular valves Prosthetic joints
Cerebrospinal fluid shunts Silicone rubber prosthesis
Contact or intraocular lenses Stents
Dental implants Tissue fillers
Electrical dialyzers Urinary catheters
Endotracheal tubes Ventriculoperitoneal shunts
Implanted prosthetic devices for erectile dysfunction Voice prostheses
Fig. 3: polymicrobial biofilms detected on orthodontic appliances visualised by scanning electron microscopy (SEM). The SEM images reveal 
the presence of different microbial groups, including bacteria and fungi, and an extracellular matrix (arrows). Bars, 5 µm.
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nents using hydrolytic enzymes such as DNases, glycosi-
dases, lipases, and proteases; surfactants; chelator agents; 
biocides; or inhibitors of quorum sensing systems).(34,49,50) 
With these ideas in mind, it is likely that an effective anti-
biofilm strategy will emerge from a fluid and dynamic 
cross-talk involving distinct biomedical disciplines.
An additional relevant issue that must be highlighted 
is the fact that the currently used antimicrobial agents in 
the clinical arena were developed to act on planktonic 
cells. As such, these prescription drugs are essentially 
only effective against microbial cells during their expo-
nential growth phase, and consequently, are either poorly 
effective or totally ineffective against cells in a biofilm. 
For example, biofilm-forming microbial cells can have 
from 10 to > 1,000-fold greater minimum inhibitory con-
centration of classical antimicrobial drugs compared to 
their planktonic counterparts when treated under labora-
tory conditions.(7,51) All of these facts emphasise the ne-
cessity to perform susceptibility testing on new drug 
formulations using biofilm-forming microbial cells as 
a routine in both research labs and hospital settings, as 
well as in clinical trials. In order to reach this utopic, 
ideal, simple, cheap, rapid, reproducible, rigorous, and 
responsive in vitro test should be standardised and vali-
dated. Furthermore, its efficacy should be proven to aid 
in predicting in vivo outcomes.
Conclusions and perspectives - The authors sincere-
ly hope that the present mini-review arouses enthusiasm 
and scientific curiosity in students, teachers, and re-
searchers worldwide since the intriguing and unique bio-
film lifestyle of several microorganisms continues to be 
a challenge for both basic and applied research areas in 
clinical, industrial, and environmental fields across the 
academic and industry platforms. Without a doubt, due 
to the high level of tolerance/resistance shown by mature 
biofilms, it becomes a tremendously arduous task, many 
times impossible, to manage and eradicate biofilm-as-
sociated disease solely by conventional antimicrobial 
chemotherapy. Thus, we need to intensify our studies on 
microbial biofilms with the aim of deciphering and de-
feating this complex and robust social cooperation. With 
this perspective in mind, it is reasonable to expect that 
the combined herculean efforts in anti-biofilm research 
will lead to substantial improvements in both pharma-
ceuticals and medical practices.
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